ANI PHARMACEUTICALS INC
For the period ended Sep 30, 2025. Filed Nov 7, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2025 · Filed Nov 7, 2025
ANIP$71.25+5.1%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Cash Flows
| Nine Months Ended September 30, | ||
|---|---|---|
| 2025 | 2024 | |
| Cash Flows From Operating Activities | ||
| Net income (loss) | $50,847 | $(8,246) |
| Adjustments to reconcile net income to net cash and cash equivalents provided by operating activities: | ||
| Stock-based compensation | 28,161 | 22,283 |
| Deferred taxes | 11,881 | (4,383) |
| Depreciation and amortization | 68,804 | 45,131 |
| Unrealized gain on investment in equity securities | (2,551) | (8,298) |
| Non-cash operating lease expense | 1,204 | 1,134 |
| Non-cash interest | 1,005 | 319 |
| Contingent consideration fair value adjustment | (25,285) | 1,274 |
| Loss (gain) on disposal of assets | 295 | (5,347) |
| Loss on debt extinguishment | — | 7,468 |
| Amortization of inventory step up | — | 3,224 |
| Asset impairment charges | 767 | — |
| Changes in operating assets and liabilities: | ||
| Accounts receivable, net | (30,674) | 4,426 |
| Inventories | (9,693) | (20,612) |
| Prepaid expenses and other assets | (564) | 3,822 |
| Accounts payable | 22,391 | 7,300 |
| Accrued royalties | 28,621 | 7,171 |
| Income taxes | (16,003) | (14,268) |
| Accrued government rebates | 18,318 | (1,475) |
| Returned goods reserve | 10,731 | 4,296 |
| Accrued expenses, accrued compensation, and other | (3,397) | 2,938 |
| Net Cash and Cash Equivalents Provided by Operating Activities | 154,858 | 48,157 |
| Cash Flows From Investing Activities | ||
| Acquisition of Alimera, net of cash acquired | — | (393,079) |
| Acquisition of product rights, intangible assets, and other related assets | (20,327) | (631) |
| Acquisition of property and equipment, net | (12,591) | (13,842) |
| Proceeds from the sale of building | — | 13,514 |
| Net Cash and Cash Equivalents Used in Investing Activities | (32,918) | (394,038) |
| Cash Flows From Financing Activities | ||
| Proceeds from convertible notes | — | 316,250 |
| Proceeds from term loan | — | 325,000 |
| Purchase of capped call transaction | — | (40,575) |
| Repayment on borrowings under credit agreement | — | (292,500) |
| Debt issuance costs | — | (15,376) |
| Principal payments on borrowings | (6,093) | (1,500) |
| Series A convertible preferred stock dividends paid | (1,157) | (1,219) |
| Proceeds from stock option exercises and ESPP purchases | 13,566 | 4,788 |
| Treasury stock purchases for restricted stock vests | (11,598) | (10,641) |
| Payments on contingent consideration | (26) | (12,500) |
| Payment of accrued licensor payments | — | (1,875) |
| Net Cash and Cash Equivalents (Used in) Provided by Financing Activities | (5,308) | 269,852 |
| Effect of Exchange Rate Changes on Cash, Cash Equivalents and Restricted Cash | 1,120 | (75) |
| Net Change in Cash, Cash Equivalents, and Restricted Cash | 117,752 | (76,104) |
| Cash, cash equivalents, and restricted cash, beginning of period | 144,894 | 221,121 |
| Cash, cash equivalents, and restricted cash end of period | $262,646 | $145,017 |
| Nine Months Ended September 30, | ||
|---|---|---|
| 2025 | 2024 | |
| Reconciliation of cash, cash equivalents, and restricted cash, beginning of period | ||
| Cash and cash equivalents | $144,861 | $221,121 |
| Restricted cash | 33 | — |
| Cash, cash equivalents, and restricted cash, beginning of period | $144,894 | $221,121 |
| Reconciliation of cash, cash equivalents, and restricted cash, end of period | ||
| Cash and cash equivalents | $262,610 | $144,982 |
| Restricted cash | 36 | 35 |
| Cash, cash equivalents, and restricted cash, end of period | $262,646 | $145,017 |
| Supplemental disclosure for cash flow information: | ||
| Cash paid for interest, net of amounts capitalized | $22,318 | $19,232 |
| Cash paid for income taxes | $16,613 | $17,214 |
| Supplemental non-cash investing and financing activities: | ||
| Conversion of convertible preferred stock into common stock | $24,850 | $— |
| Right of use assets obtained in exchange for new operating lease liabilities | $5,244 | $— |
| Property and equipment purchased and included in accounts payable | $1,029 | $635 |
| Purchase consideration for Alimera Acquisition | $— | $(16,523) |
| Accrued deferred financing costs | $— | $(1,976) |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.